XML 66 R47.htm IDEA: XBRL DOCUMENT
v3.22.4

Royalty and Commercial Payment Purchase Agreements - Agenus (Details) $ in Thousands |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Sep. 20, 2018 USD ($) product | Nov. 30, 2020 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Agreements |  |  |  |  |
Long-term royalty and commercial payment receivables |  |  | $ 63,683 | $ 69,075 | $ 34,575
Impairment of long-term royalty receivable |  |  | 0 | $ 0 |
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus |  |  |  |  |
Agreements |  |  |  |  |
Amount of milestone achieved |  | $ 10,000 |  |  |
Agenus | Royalty Purchase Agreement |  |  |  |  |
Agreements |  |  |  |  |
Payments related to purchase of royalty rights and other commercial payment rights | $ 15,000 |  |  |  |
Long-term royalty and commercial payment receivables | $ 15,000 |  |  |  |
Impairment of long-term royalty receivable |  |  | $ 0 |  |
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets |  |  |  |  |
Agreements |  |  |  |  |
Royalties entity has right to receive (as a percent) | 33.00% |  |  |  |
Number of licensed products related to milestone and royalties | product | 6 |  |  |  |
Purchased percentage of milestones | 10.00% |  |  |  |
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product |  |  |  |  |
Agreements |  |  |  |  |
Royalties entity has right to receive (as a percent) | 33.00% |  |  |  |
Purchased percentage of milestones | 10.00% |  |  |  |
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones | $ 59,500 |  |  |  |
Amount of milestone achieved |  | 1,000 |  |  |
Cash receipts for achievement of contractual milestones |  | $ 1,000 |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash receipts for achievement of contractual milestones. + References No definition available. + Details
Name: | xoma_CashReceivedForAchievementOfContractualMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-term royalty and commercial rights receivables, non current. + References No definition available. + Details
Name: | xoma_LongTermRightsReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of milestone achieved. + References No definition available. + Details
Name: | xoma_MilestoneAchieved
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of licensed products related to milestones and royalties purchased. + References No definition available. + Details
Name: | xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments related to purchase of royalty rights and other commercial payment rights. + References No definition available. + Details
Name: | xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones. + References No definition available. + Details
Name: | xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchased percentage of milestones. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfMilestones
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalties entity has the right to receive as a percentage. + References No definition available. + Details
Name: | xoma_RoyaltyReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AgenusIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |